Tesla slips as group sets lower annual sales goal amid SpaceX merger talk

Tesla shares fell in premarket trading after the company set a decade-end sales target of 5 million vehicles, down from Elon Musk’s prior projection of 20 million, and tempered expectations for Optimus and Robotaxi; Tesla said Robotaxi may not be financially material until late 2027 or 2028. Quarterly revenue was flat at $28.05 billion and net profit fell 4% to $1.7 billion, though adjusted EPS of $0.48 beat the $0.45 consensus, automotive gross margin excluding regulatory credits rose to 18.1%, and free cash flow recovered to $1.53 billion. Tesla expects about $20 billion in capital expenditures this year and Musk said the Terafab chip venture could cost more than $100 billion long term. Shares were down 14.1% year to date, while Tesla and SpaceX formed committees to explore a possible merger, with no deal guaranteed.

Analysis

The key issue is a widening gap between Tesla’s nearer-term earnings engine and the assets now carrying much of its valuation narrative. Better automotive margins and positive free cash flow provide a cushion, but they do not yet establish that robotics, Robotaxi, or in-house chips can replace vehicle growth. The lower sales ambition weakens the scale-up case for the core business; meanwhile, ambitious AI projects extend the duration and capital intensity of the upside case. That combination leaves TSLA particularly exposed to execution delays and higher discount rates.

Near term, the reduced capex estimate may ease cash-flow concerns, but verify whether it reflects genuine scope reduction or merely timing before treating it as a durable improvement. Over 1–3 months, the largest event risk is the proposed TSLA–SPCX combination: committee exploration is not a transaction. Terms, relative valuations, governance, and which entity funds the capital program matter more than headline strategic fit. A deal could also redirect investor attention from operating performance to financing and related-party questions. Over 6–18 months, Terafab competes for capital against vehicle investment; chip self-sufficiency is not valuable to equity holders unless it improves cost, supply access, or product capability enough to justify the spend.

Contrarian point: the weak share performance may already reflect skepticism toward the AI pivot, while improving auto margins argue against assuming the core business is deteriorating irreversibly. But sentiment catalysts are not earnings catalysts: management’s own timelines imply limited near-term contribution from autonomy and robotics.

Key Decisions for Investors

• Avoid chasing the earnings reaction in either direction; keep TSLA exposure modest until management clarifies the balance between automotive investment and AI-related capital allocation.
• For a relative-value expression, consider an underweight in TSLA versus a diversified large-cap technology or broad-market exposure rather than an outright short. Reassess if automotive gross-margin ex-credits reverses or cash flow weakens as capex rises.
• Treat any TSLA–SPCX merger headline as a terms-driven catalyst, not automatic value creation. Before trading it, verify exchange ratio, financing, governance protections, and which entity bears Terafab spending; absent those details, use an alert rather than a merger-arbitrage position.
• Falsifiers to the cautious thesis: sustained automotive margin improvement accompanied by resilient deliveries and free cash flow, or verifiable commercial milestones in Robotaxi/Optimus. Conversely, renewed margin compression, capex rising without corresponding milestones, or adverse merger terms would strengthen the underweight case.